Retatrutide
First-ever triple-action weight management peptide targeting three receptors at once: GIP, GLP-1, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.
€149.99
€179.99
Save 17%15mg
Payment Methods
Lab Report (COA)
What is Retatrutide?
Retatrutide (LY3437943) is the first triple-acting peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. The addition of glucagon receptor agonism introduces thermogenesis and enhanced hepatic fat oxidation - a dimension missing from dual agonists.
Why It Matters
Retatrutide (LY3437943) is a novel triple-agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. While current mono- and dual-agonists target 1-2 pathways, Retatrutide engages all three metabolic signaling axes. Phase 2 clinical data reported up to 24% mean body weight reduction - among the highest observed in incretin-based research.
Key Research Areas
- Weight loss - up to 24% mean body weight reduction in Phase 2 trials (approaching bariatric surgery outcomes)
- Triple mechanism - appetite suppression (GLP-1) + metabolic enhancement (GIP) + energy expenditure (glucagon)
- Liver fat - glucagon-driven hepatic fat oxidation, relevant for MASLD research
- Cardiovascular - improvements across blood pressure, triglycerides, and CRP
Specifications
- Purity: ≥98% (HPLC & mass spectrometry)
- Form: Lyophilized powder
- Storage: 2–8°C after reconstitution, use within 4 weeks
- CoA: Included
Related: Semaglutide | Tirzepatide
For Research Purposes Only.
